Selzentry Related Clinical Trials
Switching Undetectables to Selzentry [Completed]
Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I) [Completed]
The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers [Recruiting]
Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects [Completed]
Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects [Terminated]
A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects [Completed]
Safety Study of Maraviroc's Effect on Human Osteoclasts [Completed]
Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue [Completed]
Effect Of Maraviroc On The Pharmacokinetics Of Digoxin [Completed]
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children [Active, not recruiting]
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With Ccr5 Tropic HIV 1 [Terminated]
Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc [Completed]
Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites [Completed]
Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects [Completed]
A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients [Completed]
Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers [Completed]
Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation [Completed]
Maraviroc Abacavir STudy - Effect on Endothelial Recovery [Recruiting]
Maraviroc and NeuroAIDS Pathogenesis [Not yet recruiting]
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure [Completed]
Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women [Recruiting]
A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy [Completed]
Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS) [Enrolling by invitation]
A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects [Completed]
Maraviroc as GVHD Prophylaxis in Transplant Recipients [Recruiting]
Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients [Active, not recruiting]
Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1 [Completed]
A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium [Withdrawn]
Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function [Completed]
Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression [Completed]
Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA) [Recruiting]
PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen [Completed]
MARCH Central Nervous System Substudy [Active, not recruiting]
Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients [Recruiting]
Impact of CCR5 Inhibition on Sarcoidosis Immunophenotypes [Recruiting]
A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc [Completed]
Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus [Completed]
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients [Withdrawn]
First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers [Completed]
Maraviroc Immune Recovery Study [Completed]
Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) [Terminated]
A Open-label, Drug-Drug Interaction With Maraviroc [Recruiting]
Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring [Completed]
Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine [Completed]
Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy [Terminated]
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc [Terminated]
Impact of Maraviroc on the Immune Function in HIV-1 Infected Subjects Receiving Immunisation With Novel Antigens [Terminated]
Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients [Active, not recruiting]
Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects [Completed]
Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women [Completed]
Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 [Not yet recruiting]
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B [Completed]
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients [Active, not recruiting]
Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia [Completed]
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects [Completed]
A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants [Completed]
Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc [Completed]
Intense Acute Infection Study [Completed]
Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults [Recruiting]
Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen [Completed]
Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels [Active, not recruiting]
Concentrations of Maraviroc in the Semen of HIV-Infected Men [Completed]
The Maraviroc Central Nervous System (CNS) Study [Completed]
Maraviroc in Rheumatoid Arthritis [Terminated]
Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan) [Active, not recruiting]
Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection [Recruiting]
The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study [Completed]
Maraviroc 300 mg Twice Daily in HIV Negative Male Volunteers [Completed]
Maraviroc Compassionate Use [Withdrawn]
MARCH Vascular Endothelium Substudy [Active, not recruiting]
MARCH Renal Substudy [Active, not recruiting]
Switch to Maraviroc + Integrase Inhibitor [Recruiting]
Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women [Active, not recruiting]
Non-Interventional Study Of Celsentri� In Treatment Experienced Patients With CCR5-Tropic HIV-Infection [Completed]
Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects [Completed]
Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01) [Completed]
A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India [No longer available]
Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus [Completed]
Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1 [Completed]
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir [Completed]
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) [Recruiting]
An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc [Active, not recruiting]
Effect of Maraviroc on Endothelial Function in HIV-Infected Patients [Completed]
Multicenter, Safety Study Of Maraviroc [Completed]
CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery [Completed]
Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication [Recruiting]
IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults [Completed]
Integrase and Maraviroc Intensification for Neurocognitive Dysfunction (InMIND) [Not yet recruiting]
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP) [Completed]
A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study [Recruiting]
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine [Completed]
|